Stock Evaluator: Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals, Inc. LXRX

$1.53 -0.14 -8.38%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 4,203,003
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Commentary & Analysis


Financial Summary

Share Statistics LXRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $681.2 $421.5 43%
Shares Out (Mil) 445.0 46.9 87%
Institutional Ownership 96.0% 82.0% 68%
Float (Mil) 219.2 49.2 75%
Beta 1.08 0.68 64%
Avg Daily Volume (000s) 2,408 347 83%
Price Change
(52-week)
5.5% 49.3% 59%
Growth LXRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 15.7% 6.4% 74%
Net Income (5yr) 3.0% (1.3%) 44%
EPS (5yr) 23.4% 15.1% 74
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (15.0%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 5 5 6
Current EPS ($0.054) ($0.159) ($0.213)
Month Ago EPS ($0.036) ($0.166) ($0.191)
# Rev Up 1 0 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.036) ($0.166) ($0.191)
Year/Year Chg 74.2% 14.4% (23.0%)
Financials LXRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $39 $275 18%
Net Income (TTM) (Mil) ($62) ($11) 14%
EPS (TTM) ($0.151) ($0.700) 34%
Operating Cash Flow (TTM) (Mil) ($49) ($7) 10%
Net Cash Flow (TTM) (Mil) ($35) $1 24%
Long-Term Debt (Q1) (Mil) $58 $6 40%
Enterprise Value (Q1) (Mil) $669 $331 37%
Valuation LXRX Industry
Median
Percentile
(All Stocks)
P/B 4.14 2.08 78%
P/E na 20.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios LXRX Industry
Median
Percentile
(All Stocks)
Gross Margin 91.4% 69.5% 94%
Net Margin (161.8%) 3.6% 6%
ROA (27.8%) (23.8%) 17%
ROE (43.9%) (24.2%) 16%
Liabilities to Assets 32.3% 31.6% 23%
F-Score 2 3 7%

Lexicon Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors